Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

GastroEsophageal Cancer Clinical Trial

Official title:

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03647969
• Other study ID #: AIO-STO-0417
• Secondary ID: 2017-002080-18CA
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 7, 2018
• Est. completion date: March 2024

Study information

• Verified date: July 2023
• Source: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX, with modified FOLFOX plus Nivolumab and Ipilimumab or FLOT plus Nivolumab. The groups will be compared for time until progression of the disease (primary endpoint) as well as for response to the treatment, overall survival, safety/tolerability of the treatment and quality of life.

Description:

This is a randomized, open labelled multicenter phase II trial, followed by a non-randomized arm.

Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be randomized to receive either modified FOLFOX (Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2), every 2 weeks) alone, modified FOLFOX plus Nivolumab (240mg "Flatdose" i.v. d1 every 2 weeks) and Ipilimumab (1mg/kg i.v. d1 every 6 weeks) or sequential treatment (three cycles of induction chemotherapy with modified FOLFOX followed by immunotherapy consisting of 4 administrations of Nivolumab at 240mg "Flatdose" i.v. d1 every 2 weeks and 2 administrations of Ipilimumab at 1mg/kg i.v. d1 every 6 weeks, this sequence may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision; after completion or discontinuation of chemotherapy, immunotherapy will be continued consisting of Nivolumab at 240mg "Flatdose" i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks). In a non-randomized arm, patients receive Nivolumab 240mg "Flatdose" i.v. d1 every 2 weeks and FLOT (Docetaxel 50mg/², Oxaliplatin 85 mg/m², leucovorin 200 mg/m² on day 1 and fluorouracil 2600 mg/m² IV continuous infusion over 24 hours) every 2 weeks. After completion or discontinuation of chemotherapy, immunotherapy may be continued (Nivolumab at 240mg "Flatdose" i.v. d1 every 2 weeks).

Treatment in every arm will be given for a maximum of 24 months or until disease progression or inacceptable toxicity or end of study treatment.

The primary objective is to determine the clinical performance of the experimental regimen in patients with previously untreated HER2 negative locally advanced or metastatic esophagogastric adenocarcinoma in terms of progression free survival (acc. to RECIST v1.1).

Secondary objectives are to determine efficacy in terms of objective response rate (acc. to RECIST v1.1) and overall survival, as well as tolerability (acc. to NCI CTC AE v4.03) of the experimental regimen. In addition histopathological types and molecular parameters such as immune cell composition and PD-L1 expression as determined by quantitative mRNA (RT-PCR) will be correlated with efficacy in an exploratory analysis.

257 subjects (59 in the control arm, 89 in the experimental treatment group A1, 59 in the experimental treatment group A2 and 50 in the experimental treatment group C) will be enrolled.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 262
• Est. completion date: March 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. All subjects must have inoperable, advanced or metastatic GC or GEJ adenocarcinoma.

2. Subjects must have HER2-negative disease defined as either IHC 0 or I+ or IHC 2+, the latter in combination with ISH-, as assessed locally on a primary or metastatic tumour.

3. Subject must be previously untreated with systemic treatment given as primary therapy for advanced or metastatic disease.

4. Prior adjuvant or neoadjuvant chemotherapy, radiotherapy and/or chemoradiotherapy are permitted as long as the last administration of the last regimen (whichever was given last) occurred at least 6 months prior to randomization/enrolment.

5. Palliative radiotherapy is allowed and must be completed 2 weeks prior to randomization/enrolment.

6. Subjects must have measurable or evaluable non-measurable disease as assessed by the investigator, according to RECIST v1.1 (Appendix D).

7. ECOG performance status score of 0 or 1 (Appendix B).

8. Life expectancy > 12 weeks

9. Screening laboratory values must meet the following criteria (using NCI CTCAE v.4.03):

1. WBC = 2000/uL

2. Neutrophils = 1500/µL

3. Platelets = 100x10^3/µL

4. Hemoglobin = 9.0 g/dL

5. Serum creatinine = 1.5 x ULN

6. AST = 3.0 x ULN (or = 5.0X ULN if liver metastates are present)

7. ALT = 3.0 x ULN (or = 5.0X ULN if liver metastates are present)

8. Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0 x ULN)

10. Males and Females* = 18 years of age

*There are no data that indicate special gender distribution. Therefore patients will be enrolled in the study gender-independently.

11. Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.

12. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.

13. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. Women must not be breastfeeding.

14. WOCBP must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo 5 half-lives. The terminal half-lives of nivolumab and ipilimumab are approximately 25 days and 15 days, respectively. WOCBP should use an adequate method to avoid pregnancy for approximately 5 months (30 days plus the time required for nivolumab to undergo 5 half-lives) after the last dose of investigational drug.

15. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo 5 half-lives. The terminal half-lives of nivolumab and ipilimumab are approximately 25 days and 15 days, respectively. Males who are sexually active with WOCBP must continue contraception for approximately 7 months (90 days plus the time required for nivolumab to undergo 5 half-lives) after the last dose of investigational drug. In addition, male subjects must be willing to refrain from sperm donation during this time.

Exclusion Criteria:

1. Malignancies other than disease under study within 5 years prior to inclusion, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS > 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)

2. Subjects with untreated symptomatic CNS metastases. Subjects are eligible if CNS metastases are asymptomatic (this includes patients with unknown CNS metastatic status who have no clinical signs of CNS metastases) or those with asymptomatic or symptomatic CNS who are adequately treated and are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to randomization/enrolment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of < 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization/enrolment. Patients with unknown CNS metastatic status and any clinical signs indicative of CNS metastases are eligible if CNS metastases are excluded using CT and/or MRI scans, or CNS metastases are confirmed but adequately treated as described above.

3. Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. For any cases of uncertainty, it is recommended that the medical monitor be consulted prior to signing informed consent.

4. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

5. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

6. All toxicities attributed to prior anti-cancer therapy other than hearing loss, alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 4.03) or baseline before administration of study drug.

7. > Grade 1 peripheral neuropathy according to CTCAE version 4.0

8. Known Dihydropyrimidine dehydrogenase (DPD) deficiency

9. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the subject to receive study drug.

10. Ascites which cannot be controlled with appropriate interventions.

11. Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry; congestive heart failure NYHA grade 3 and 4

12. Significant acute or chronic infections including, among others:

1. Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

2. Any positive test result for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.

13. History of allergy or hypersensitivity to study drugs or any constituent of the products

14. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

15. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Stomach
• GastroEsophageal Cancer

Intervention

Drug:
• Nivolumab
Nivolumab 240mg "Flatdose" i.v. d1 over 30 minutes every 2 weeks
• Ipilimumab
1mg/kg i.v. d1 over 30 minutes every 6 weeks
• mFOLFOX
Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
• FLOT
Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks * Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline.

Locations

Country	Name	City	State
Germany	Klinikum St. Marien Amberg	Amberg
Germany	Klinikum Aschaffenburg	Aschaffenburg
Germany	HELIOS Klinikum Bad Saarow	Bad Saarow
Germany	Charité CVK	Berlin
Germany	HELIOS Klinikum Berlin Buch	Berlin
Germany	Klinikum Bielefeld	Bielefeld
Germany	Städtisches Klinikum Dresden	Dresden
Germany	Universitätsklinikum TU Dresden	Dresden
Germany	Krankenhaus Nordwest	Frankfurt
Germany	Agaplesion Markus KH Frankfurt	Frankfurt/Main
Germany	Frankfurt Universitätsklinikum	Frankfurt/Main
Germany	Hämatologisch-Onkologische Praxis Altona (HOPA)	Hamburg
Germany	Hamburg Onkologische Schwerpunktpraxis Eppendorf	Hamburg
Germany	Universitätsklinikum Jena	Jena
Germany	Ortenau Klinikum Lahr	Lahr
Germany	Universitätsklinikum Lübeck	Lübeck
Germany	Klinikum Ludwigsburg	Ludwigsburg
Germany	Universitätsmedizin Mannheim	Mannheim
Germany	Universitätsklinikum Marburg	Marburg
Germany	Klinikum der Universität München Großhadern	München
Germany	Klinikum r.d. Isar	München
Germany	Studienzentrum Onkologie Ravensburg	Ravensburg
Germany	Universitätsklinikum Tübingen	Tübingen
Germany	Universitätsklinikum Ulm	Ulm
Germany	Klinikum Weiden	Weiden
Germany	Helios Dr. Horst Schmidt Kliniken	Wiesbaden
Germany	Klinikum Wolfsburg	Wolfsburg

Sponsors (1)

Lead Sponsor	Collaborator
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS) Arm A and B	PFS, defined as time from randomization to the date of first observed disease progression as assessed by the investigator using CT criteria or death from any cause assessed every 8 weeks for up to 3 years Arm A versus Arm B	Up to 3 years
Primary	Progression-free Survival rate at 6 months Arm A2 and C	PFS rate at 6 months is defined as proportion of patients being known to be alive and free of disease progression as assessed by the investigator using CT criteria at 6 months after randomization/enrolment	6 months after randomization/enrolment
Secondary	Progression-free survival (PFS) Arm A1, A2, C	PFS, defined as time from randomization/enrolment to the date of first observed disease progression as assessed by the investigator using CT criteria or death from any cause assessed every 8 weeks for up to 3 years for Arm A1, Arm A2 and Arm C	Up to 3 years
Secondary	Progression-free Survival rate at 6 months Arms A and B	PFS rate at 6 months is defined as proportion of patients being known to be alive and free of disease progression as assessed by the investigator using CT criteria at 6 months after randomization	6 months after randomization
Secondary	Overall Response Rate (ORR)	ORR defined as proportion of patients with complete or partial response (CR + PR) as assessed according to RECIST criteria every 8 weeks for up to 2 years	Up to 2 years
Secondary	Duration of response and disease stabilization	Duration of response and disease stabilization defined as time from documentation of tumor response (CR, PR) or disease stabilization (SD) according to RECIST criteria to disease progression or death for up to 3 years	Up to 3 years
Secondary	Overall survival (OS)	Overall survival according to Kaplan-Meier assessed from randomization/enrolment to the date of death from any cause	Up to 3 years
Secondary	Incidence and severity of adverse events	incidence and severity of adverse events according to CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 criteria as assessed every 2 weeks during treatment and until 100 days after the last dose of study drug	Up to 27 months
Secondary	Patient reported outcomes: Quality of life	Quality of life as measured by questionnaire EORTC-QLQ-C30 from randomization every 8 weeks until EOT and afterwards every 3 months until first observed disease progression or death for up to 3 years	Up to 3 years
Secondary	Progression-free survival (PFS) by PD-L1 expression status	Subgroup analysis of PFS, defined as time from randomization/enrolment to the date of first observed disease progression as assessed by the investigator using CT criteria or death from any cause assessed every 8 weeks for up to 3 years, according to PD-L1 expression status	Up to 3 years
Secondary	Overall survival (OS) by PD-L1 expression status	Subgroup analysis of overall survival according to Kaplan-Meier assessed from randomization/enrolment to the date of death from any cause according to PD-L1 expression status	Up to 3 years